Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder

Overview

Journal Am J Psychiatry

Specialty Psychiatry

Date 2015 Nov 11

PMID 26552940

Citations 50

Authors

Ewgeni Jakubovski

Anjali L Varigonda

Nicholas Freemantle

Matthew J Taylor

Michael H Bloch

Affiliations

Soon will be listed here.

Abstract

Objective: Previous studies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major depressive disorder follows a flat response curve within the therapeutic dose range. The present study was designed to clarify the relationship between dosage and treatment response in major depressive disorder.

Method: The authors searched PubMed for randomized placebo-controlled trials examining the efficacy of SSRIs for treating adults with major depressive disorder. Trials were also required to assess improvement in depression severity at multiple time points. Additional data were collected on treatment response and all-cause and side effect-related discontinuation. All medication doses were transformed into imipramine-equivalent doses. The longitudinal data were analyzed with a mixed-regression model. Endpoint and tolerability analyses were analyzed using meta-regression and stratified subgroup analysis by predefined SSRI dose categories in order to assess the effect of SSRI dosing on the efficacy and tolerability of SSRIs for major depressive disorder.

Results: Forty studies involving 10,039 participants were included. Longitudinal modeling (dose-by-time interaction=0.0007, 95% CI=0.0001-0.0013) and endpoint analysis (meta-regression: β=0.00053, 95% CI=0.00018-0.00088, z=2.98) demonstrated a small but statistically significant positive association between SSRI dose and efficacy. Higher doses of SSRIs were associated with an increased likelihood of dropouts due to side effects (meta-regression: β=0.00207, 95% CI=0.00071-0.00342, z=2.98) and decreased likelihood of all-cause dropout (meta-regression: β=-0.00093, 95% CI=-0.00165 to -0.00021, z=-2.54).

Conclusions: Higher doses of SSRIs appear slightly more effective in major depressive disorder. This benefit appears to plateau at around 250 mg of imipramine equivalents (50 mg of fluoxetine). The slightly increased benefits of SSRIs at higher doses are somewhat offset by decreased tolerability at high doses.

Citing Articles

Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses to treatment.

Gomeni R, Bressolle-Gomeni F J Pharmacokinet Pharmacodyn. 2024; 52(1):5.

PMID: 39656323 PMC: 11631816. DOI: 10.1007/s10928-024-09950-7.

Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Parkinson's Disease: A Systematic Review and Meta-Analysis.

Gao R, Zhao P, Yan K Clin Drug Investig. 2024; 44(7):459-469.

PMID: 38960993 DOI: 10.1007/s40261-024-01378-8.

The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and Adults.

Mills J, Mendez E, Strawn J J Child Adolesc Psychopharmacol. 2024; 34(7):302-309.

PMID: 38800869 PMC: 11807899. DOI: 10.1089/cap.2024.0016.

A framework for inferring and analyzing pharmacotherapy treatment patterns.

Rush E, Ozmen O, Kim M, Ortegon E, Jones M, Park B BMC Med Inform Decis Mak. 2024; 24(1):68.

PMID: 38459459 PMC: 10924394. DOI: 10.1186/s12911-024-02469-4.

Effects of Antidepressants on Sleep in Post-traumatic Stress Disorder: An Overview of Reviews.

Lappas A, Polyzopoulou Z, Christodoulou N, Bozikas V, Samara M Curr Neuropharmacol. 2023; 22(4):749-805.

PMID: 37533247 PMC: 10845105. DOI: 10.2174/1570159X21666230801144328.

References

Baker C, Tweedie R, Duval S, Woods S . Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety. 2003; 17(1):1-9. DOI: 10.1002/da.10079. View

Claghorn J, Kiev A, Rickels K, Smith W, Dunbar G . Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry. 1992; 53(12):434-8. View

Kessler R, Berglund P, Demler O, Jin R, Merikangas K, Walters E . Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):593-602. DOI: 10.1001/archpsyc.62.6.593. View

Lydiard R, Laird L, MORTON Jr W, Steele T, Kellner C, Laraia M . Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull. 1989; 25(1):68-70. View

Detke M, Wiltse C, Mallinckrodt C, McNamara R, Demitrack M, Bitter I . Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004; 14(6):457-70. DOI: 10.1016/j.euroneuro.2004.01.002. View

Tollefson G, Holman S . How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo. Int Clin Psychopharmacol. 1994; 9(4):245-50. DOI: 10.1097/00004850-199400940-00003. View

March J, Kobak K, Jefferson J, Mazza J, Greist J . A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatry. 1990; 51(5):200-2. View

Taylor M, Freemantle N, Geddes J, Bhagwagar Z . Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch Gen Psychiatry. 2006; 63(11):1217-23. PMC: 2211759. DOI: 10.1001/archpsyc.63.11.1217. View

Fabre L, Abuzzahab F, Amin M, Claghorn J, MENDELS J, Petrie W . Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo. Biol Psychiatry. 1995; 38(9):592-602. DOI: 10.1016/0006-3223(95)00178-8. View

10.

Feighner J, OVERO K . Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression. J Clin Psychiatry. 2000; 60(12):824-30. DOI: 10.4088/jcp.v60n1204. View

11.

Turner E, Matthews A, Linardatos E, Tell R, Rosenthal R . Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008; 358(3):252-60. DOI: 10.1056/NEJMsa065779. View

12.

Nierenberg A, Greist J, Mallinckrodt C, Prakash A, Sambunaris A, Tollefson G . Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007; 23(2):401-16. DOI: 10.1185/030079906X167453. View

13.

Kessler R, Chiu W, Demler O, Merikangas K, Walters E . Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):617-27. PMC: 2847357. DOI: 10.1001/archpsyc.62.6.617. View

14.

Feighner J, COHN J, FABRE Jr L, Fieve R, MENDELS J, Shrivastava R . A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord. 1993; 28(2):71-9. DOI: 10.1016/0165-0327(93)90035-i. View

15.

Fabre L, Birkhimer L, Zaborny B, Wong L, Kapik B . Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. Int Clin Psychopharmacol. 1996; 11(2):119-27. View

16.

Bloch M, McGuire J, Landeros-Weisenberger A, Leckman J, Pittenger C . Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Mol Psychiatry. 2009; 15(8):850-5. PMC: 2888928. DOI: 10.1038/mp.2009.50. View

17.

Trivedi M, Pigotti T, Perera P, Dillingham K, Carfagno M, Pitts C . Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. J Clin Psychiatry. 2004; 65(10):1356-64. DOI: 10.4088/jcp.v65n1010. View

18.

Rudolph R, Feiger A . A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord. 2000; 56(2-3):171-81. DOI: 10.1016/s0165-0327(99)00067-1. View

19.

Heiligenstein J, Tollefson G, Faries D . Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo. J Affect Disord. 1994; 30(3):163-73. DOI: 10.1016/0165-0327(94)90077-9. View

20.

Smith W, Glaudin V . A placebo-controlled trial of paroxetine in the treatment of major depression. J Clin Psychiatry. 1992; 53 Suppl:36-9. View